Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives.

MLA

Manolis, Antonis A., et al. “Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives.” Vascular Health and Risk Management, vol. 15, Dec. 2019, pp. 571–79. EBSCOhost, https://doi.org/10.2147/VHRM.S210150.

APA

Manolis, A. A., Manolis, T. A., Melita, H., & Manolis, A. S. (2019). Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives. Vascular Health and Risk Management, 15, 571–579. https://doi.org/10.2147/VHRM.S210150

Chicago

Manolis, Antonis A, Theodora A Manolis, Helen Melita, and Antonis S Manolis. 2019. “Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives.” Vascular Health and Risk Management 15 (December): 571–79. doi:10.2147/VHRM.S210150.